| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/15/2004 | CA2491217A1 New drug combinations based on sodium channel blockers and magnesium salts |
| 01/15/2004 | CA2491132A1 Estrieno[3,2-b]/[3,4-c]pyrrole derivatives useful as modulators of the estrogen receptors |
| 01/15/2004 | CA2491127A1 Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use |
| 01/15/2004 | CA2491074A1 O-derivatized nocathiacin derivatives |
| 01/15/2004 | CA2491054A1 Compositions of hyaluronic acid and methods of use |
| 01/15/2004 | CA2491029A1 Substituted aryl boronic acids, their preparation and their precursors |
| 01/15/2004 | CA2490988A1 Use of cetp inhibitors and antihypertensive agents as well as optionally hmg coa reductase inhibitors |
| 01/15/2004 | CA2490983A1 Immunostimulation by chemically modified rna |
| 01/15/2004 | CA2490978A1 Controlled-release pharmaceutical formulations |
| 01/15/2004 | CA2490952A1 Vitamin-containing system for stabilising the immune response of animals |
| 01/15/2004 | CA2490714A1 Use of alanyl-aminopeptidase inhibitors and pharmaceutical compositions containing said inhibitors |
| 01/15/2004 | CA2490707A1 Method of using ryanodine antagonists in treating neural injury |
| 01/15/2004 | CA2490579A1 Methods for specifically inhibiting histone deacetylase-7 and 8 |
| 01/15/2004 | CA2490494A1 Pkc activation as a means for enhancing sapp.alpha. secretion and improving cognition using bryostatin type compounds |
| 01/15/2004 | CA2490470A1 Pyrazole urea neuropeptide y y5 receptor antagonists |
| 01/15/2004 | CA2490463A1 1-amido-4-phenyl-4-benzyloxymethyl-piperidine derivatives and related compounds as neurokinin-1(nk-1) antagonists for the treatment of emesis, depression, anxiety and cough |
| 01/15/2004 | CA2490147A1 Liquid dosage forms of non-enterically coated proton pump inhibitors |
| 01/15/2004 | CA2490145A1 Liquid dosage forms of proton pump inhibitors |
| 01/15/2004 | CA2490142A1 Liquid dosage forms of proton pump inhibitors |
| 01/15/2004 | CA2490097A1 Di-aryl-substituted-ethane pyridone pde4 inhibitors |
| 01/15/2004 | CA2489572A1 Extended-release tablets comprising divalproex sodium |
| 01/15/2004 | CA2489563A1 Compositions and methods for amelioration of human female sexual dysfunction |
| 01/15/2004 | CA2489562A1 Mitotic kinesin binding site |
| 01/15/2004 | CA2489402A1 New compounds, compositions and methods for treatment of inflammatory diseases and conditions |
| 01/15/2004 | CA2489398A1 Novel nonsteroidal anti-inflammatory substances, compositions and methods for their use |
| 01/15/2004 | CA2489396A1 Utilization of heteroarene carboxamide as dopamine-d3 ligands for the treatment of cns diseases |
| 01/15/2004 | CA2489251A1 Quinazoline derivatives |
| 01/15/2004 | CA2489071A1 Solid dispersions comprising two different polymer matrixes |
| 01/15/2004 | CA2488736A1 Use of cetp inhibitors and optionally hmg coa reductase inhibitors and/or antihypertensive agents |
| 01/15/2004 | CA2485379A1 Secondary amino anilinic piperidines as mch1 antagonists and uses thereof |
| 01/15/2004 | CA2460051A1 7,8,9,10-tetrahydro-6h-azepino, 6,7,8,9-tetrahydro-pyrido and 2,3-dihydro-2h-pyrrolo[2,1-b]-quinazolinone derivatives |
| 01/14/2004 | EP1380650A1 Conditionally replicating viral vectors and their use |
| 01/14/2004 | EP1380644A1 The use of specified TCF target genes to identify drugs for the treatment of cancer, in particular colorectal cancer, in which TCF/beta-catenin/WNT signalling plays a central role |
| 01/14/2004 | EP1380594A1 Fibroblast growth factor-10 |
| 01/14/2004 | EP1380583A2 Bis-resorcinol-triazines and their use as sunscreen agents |
| 01/14/2004 | EP1380581A1 Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative diseases |
| 01/14/2004 | EP1380579A1 Novel physiologically active substances |
| 01/14/2004 | EP1380577A1 Thiazoline acid derivatives |
| 01/14/2004 | EP1380575A1 1,2-disubstituted 1,4-dihydro-4-oxoquinoline compounds |
| 01/14/2004 | EP1380574A1 9-aminoacridine derivates and process for the preparation thereof |
| 01/14/2004 | EP1380573A2 Isoquinolines and preparation thereof |
| 01/14/2004 | EP1380571A1 Compounds useful for treating allergic and inflammatory diseases |
| 01/14/2004 | EP1380307A1 Tissue fibrosis inhibitors |
| 01/14/2004 | EP1380306A1 Remedies for psychoneurosis |
| 01/14/2004 | EP1380305A1 Photodynamic therapy for the enhancement of vascular permeability |
| 01/14/2004 | EP1380304A2 Process for the improvement of spermatozoa fertilization activity |
| 01/14/2004 | EP1380303A1 Combination therapy to treat hepatitis B virus |
| 01/14/2004 | EP1380302A1 Remedies for retina and choroid diseases containing steroids as the active ingredient |
| 01/14/2004 | EP1380301A1 Pharmaceutical combination of ethinylestradiol and dropirenone for use as a contraceptive |
| 01/14/2004 | EP1380300A1 Oestrogen and fatty acid monoester as a hypolipidaemic and antidiabetic agent |
| 01/14/2004 | EP1380299A1 Remedies for vesical stimulation in association with prostatauxe |
| 01/14/2004 | EP1380297A1 8-chloro-6, 11-dihydro-11-(4-piperidylidene)-5H-benzo[5,6]cyclo-hepta[1,2-b]pyridine oral compositions |
| 01/14/2004 | EP1380295A1 Photosensitiser and method for production thereof |
| 01/14/2004 | EP1380294A1 Preventive/remedial agent for inflammatory disease in oral-cavity mucosa and the like |
| 01/14/2004 | EP1380293A1 Bone metabolism improving agents |
| 01/14/2004 | EP1380292A1 Tiaprid for the treatment of depressions |
| 01/14/2004 | EP1380291A1 PDE IV inhibitors for treating multiple sclerosis |
| 01/14/2004 | EP1380290A1 Cross-beta structure pathway and its therapeutic relevance |
| 01/14/2004 | EP1380208A1 Disinfectant agent with antiparasitic activity |
| 01/14/2004 | EP1379876A2 Novel method for screening inhibitors of the linkage between the neuronal nitric oxide synthase associated protein and the protein inhibiting neuronal nitric oxide synthase |
| 01/14/2004 | EP1379869A1 Method for therapeutically treating a clinically recognized form of cardiopathology in a living mammal |
| 01/14/2004 | EP1379695A2 New polynucleotides and polypeptides of the ifnalpha-21 gene |
| 01/14/2004 | EP1379689A2 Oligonucleotide conjugates |
| 01/14/2004 | EP1379665A2 Gene therapy with chimeric oligonucleotides delivered by a method comprising a step of iontophoresis |
| 01/14/2004 | EP1379656A2 G-protein coupled receptor molecules and uses thereof |
| 01/14/2004 | EP1379651A2 Human genes and gene expression products isolated from human prostate |
| 01/14/2004 | EP1379649A2 Calcium binding proteins |
| 01/14/2004 | EP1379638A2 Implantation serine proteinases |
| 01/14/2004 | EP1379637A2 Nucleic acid molecules encoding a transmembran serine protease 9, the encoded polypeptides and methods based thereon |
| 01/14/2004 | EP1379630A2 Assays, methods and means relating to hypoxia inducible factor (hif) hydroxylase |
| 01/14/2004 | EP1379557A2 Use of cd25 binding molecules in steroid-resistant patients |
| 01/14/2004 | EP1379554A2 Proteins, polynucleotides encoding them and methods of using the same |
| 01/14/2004 | EP1379542A2 Treatment of tumours |
| 01/14/2004 | EP1379533A2 Novel cyclo azaphospha hydrocarbons |
| 01/14/2004 | EP1379530A1 Process for the selective preparation of 3-(z) propenyl-cephem compound |
| 01/14/2004 | EP1379529A2 Pyranocoumarin compounds as a novel pharmacophore with anti-tb activity |
| 01/14/2004 | EP1379528A1 Pyrazolopyrimidines as therapeutic agents |
| 01/14/2004 | EP1379525A2 Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| 01/14/2004 | EP1379524A2 Chromane derivatives, process for their preparation and their use as antitumor agents |
| 01/14/2004 | EP1379523A1 1,2,3,4-tetrahydroisoquinolines derivatives as urotensin ii receptor antagonists |
| 01/14/2004 | EP1379522A1 DIHYDRO-BENZO(b)(1,4)DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS I |
| 01/14/2004 | EP1379520A1 N-substituted nonaryl-heterocyclic nmda/nr2b antagonists |
| 01/14/2004 | EP1379519A1 Pyrrolidine sulfonamides |
| 01/14/2004 | EP1379518A2 Process for purifying 6-methoxy omeprazole |
| 01/14/2004 | EP1379517A2 Abca-1 elevating compounds against coronary artery disease or atherosclerosis |
| 01/14/2004 | EP1379516A1 Alkoxycarbonylamino benzoic acid or alkoxycarbonylamino tetrazolyl phenyl derivatives as ip antagonists |
| 01/14/2004 | EP1379515A1 Lipid lowering biphenylcarboxamides |
| 01/14/2004 | EP1379514A2 5-membered heterocycles, preparation and application thereof as medicaments |
| 01/14/2004 | EP1379513A1 Prodrugs of cox-2 inhibitors |
| 01/14/2004 | EP1379511A1 DIHYDRO-BENZO (b) (1, 4) DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS II |
| 01/14/2004 | EP1379510A1 Aryl and heteroaryl urea chk1 inhibitors for use as radiosensitizers and chamosensitizers |
| 01/14/2004 | EP1379509A1 A method for the preparation of oxazolidinones |
| 01/14/2004 | EP1379508A2 N-(aryl)-2-arylethenesulfonamides and therapeutic uses thereof |
| 01/14/2004 | EP1379507A1 HETEROARYL UREAS CONTAINING NITROGEN HETERO-ATOMS AS p38 KINASE INHIBITORS |
| 01/14/2004 | EP1379505A2 Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas |
| 01/14/2004 | EP1379504A1 Bipiperidinyl-derivatives and their use as chemokine receptors inhibitors |
| 01/14/2004 | EP1379503A1 Pyrrolidine sulfonamides |
| 01/14/2004 | EP1379502A1 Nicotinic acetylcholine receptor ligands |
| 01/14/2004 | EP1379501A1 Indolinones, substituted in position 6, and their use as kinase inhibitors |
| 01/14/2004 | EP1379499A1 New diaminedithiol derivatives and radiorhenium or radiotechnetium complex thereof; a liver cancer-treating composition comprising the radiorhenium complex and lipiodol; and a kit for preparation of the liver cancer-treating composition |